Peer-reviewed veterinary case report
Oral drug ABT-751 tested for lymphoma in 30 dogs
By Silver, M et al.·Published in Journal of veterinary internal medicine·2012·Animal Clinical Investigation, United States·View original on PubMed →
PetCaseFinder translated the abstract of this peer-reviewed paper into plain English so pet owners can read it. We do not publish original research — every detail traces back to the citation above. How we work →
Original publication title: Evaluation of the oral antimitotic agent (ABT-751) in dogs with lymphoma.
- Species:
- dog
Plain-English summary
A group of 30 dogs with lymphoma, either newly diagnosed or relapsed, were treated with an oral medication called ABT-751 to see how well it worked and how much they could tolerate. The maximum safe dose was found to be 350 mg/m², but some dogs experienced vomiting and diarrhea, which improved when the dosing schedule was adjusted. Out of 15 dogs in the expanded study, 3 showed positive responses to the treatment, lasting between 21 to 111 days. Overall, ABT-751 was well tolerated, suggesting it could be useful in future treatments for lymphoma or other cancers in dogs.
People also search for: dog lymphoma treatment · ABT-751 for dogs · canine cancer medication · dog vomiting after medication · lymphoma in dogs symptoms
Abstract
BACKGROUND: ABT-751 is a novel orally available antimitotic agent that targets microtubule polymerization. This mechanism may suggest potential activity in canine lymphoma. OBJECTIVE: Determine a maximum tolerated dose for ABT-751, and assess long-term tolerability and activity in canine lymphoma. ANIMALS: Thirty dogs with newly diagnosed (n = 19) or relapsed (n = 11) non-Hodgkin's lymphoma. METHODS: Dogs (n = 11) were enrolled in a rapid dose escalation study to define the maximum tolerated dose. Upon definition of a maximally tolerated dose, a cohort expansion of 19 dogs allowed verification of long-term tolerability and assessment of activity. Study endpoints in the cohort expansion included chronic tolerability, response rate, response duration, and time to progression. Additional endpoints included serum pharmacokinetics, lymph node drug concentrations, and changes in circulating endothelial cells. RESULTS: The maximum tolerated dose of ABT-751 was 350 mg/m(2) PO q24h. Dose-limiting toxicities included vomiting and diarrhea, which resolved with a schedule adjustment to 350 mg/m(2) PO q48h. ABT-751 was consistently detected in lymphoma tissue samples from dogs treated at or above the maximum tolerated dose. In the cohort expansion, objective responses were seen in 3/15 (20%) dogs with a response duration ranging from 21 to 111 days. Decreases in circulating endothelial cells were seen in 10 dogs at day 7 (2 responding dogs and 8 nonresponding dogs). CONCLUSION: ABT-751 was well tolerated at 350 mg/m(2) PO q24h for 7 days and then q48h thereafter. Activity of ABT-751 suggested a rationale for additional studies of ABT-751 as part of a combination chemotherapy protocol for lymphoma or other canine cancers.
Find similar cases for your pet
PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.
Search related cases →Original publication on PubMed: https://pubmed.ncbi.nlm.nih.gov/22369215/